Literature DB >> 15212659

Head circumference and linear growth during the first 3 years in treated congenital hypothyroidism in relation to aetiology and initial biochemical severity.

Sze May Ng1, Sze Choong Wong, Mohammed Didi.   

Abstract

AIMS: To determine the head circumference and linear growth in children with congenital hypothyroidism (CH) during the first 3 years of life in relation to the aetiology of CH and initial biochemical severity of thyroid function.
METHODS: We examined the head circumference and linear growth of 125 patients with CH from diagnosis up to 3 years of age. All infants had radionuclide scans prior to treatment. Patients were categorized into athyreosis, ectopia and dyshormonogenesis. Occipito-frontal circumference (OFC) SD, length SD, initial plasma TSH, initial plasma thyroxine (T4) and age of suppression of plasma TSH were compared between the groups. Multiple linear regression analysis was used to determine factors affecting OFC SD at 3 years of age.
RESULTS: There were 125 children in the study: athyreosis (n = 34), ectopia (n = 73) and dyshormonogenesis (n = 18). No difference was found in gestation, birth weight, age of starting L-T4 and initial dose of L-T4 in mcg/kg/day between groups. Confirmatory plasma total T4 at diagnosis was significantly lower for athyreosis when compared with ectopia and dyshormonogenesis. Median values for confirmatory TSH were significantly lower in dyshormonogenesis compared with the other two groups. At diagnosis, OFC were similar in all three groups. Children with athyreosis showed significantly larger OFCs compared with ectopia and dyshormonogenesis from 1 to 3 years. Length SD was within 1 SD of normal population standards at diagnosis and did not differ between the three groups throughout the 3 years. Spearman's correlation for OFC SD at 3 years of age showed a significant negative correlation with initial confirmatory plasma T4 (r = -0.35, P = 0.01). Multivariate analysis for OFC SD at 3 years of age showed confirmatory T4 as the only independent risk factor.
CONCLUSION: Children with athyreosis showed significantly larger OFC from 1 to 3 years of age compared with ectopia and dyshormonogenesis, independent of linear growth. Our data shows that initial confirmatory T4 at diagnosis is an independent factor influencing head growth in the first 3 years of life.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15212659     DOI: 10.1111/j.1365-2265.2004.02087.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  Growth development in children with congenital hypothyroidism: the effect of screening and treatment variables-a comprehensive longitudinal study.

Authors:  Zahra Heidari; Awat Feizi; Mahin Hashemipour; Roya Kelishadi; Massoud Amini
Journal:  Endocrine       Date:  2016-08-01       Impact factor: 3.633

2.  Primary Care Provider Management of Congenital Hypothyroidism Identified Through Newborn Screening.

Authors:  N A Rosenthal; E Bezar; S Mann; L K Bachrach; S Banerjee; M E Geffner; M Gottschalk; S K Shapira; L Hasegawa; L Feuchtbaum
Journal:  Ann Thyroid Res       Date:  2017-04-18

3.  Age estimation from fetus and infant tooth and head measurements.

Authors:  Rukiye Dagalp; P Sema Aka; Nergis Canturk; Ipek Kedici
Journal:  Int J Legal Med       Date:  2013-11-10       Impact factor: 2.686

Review 4.  An Overview on Different L-Thyroxine (l-T4) Formulations and Factors Potentially Influencing the Treatment of Congenital Hypothyroidism During the First 3 Years of Life.

Authors:  Stefano Stagi; Giovanna Municchi; Marta Ferrari; Malgorzata Gabriela Wasniewska
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

5.  Growth and specialized growth charts of children with congenital hypothyroidism detected by neonatal screening in isfahan, iran.

Authors:  Awat Feizi; Mahin Hashemipour; Silva Hovsepian; Zeynab Amirkhani; Roya Kelishadi; Maryam Yazdi; Kamal Heydari; Ali Sajadi; Masoud Amini
Journal:  ISRN Endocrinol       Date:  2013-02-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.